Antibody Genus Claim with One Working Example

The objections are strong and should be analyzed separately.

Clarity. 'Substantially reduces tumor growth' is a relative term with no assay, threshold, time point or model. The skilled person cannot tell whether a 10% reduction or a 35% reduction falls inside the claim. 'KD below 10^-9 M' is numerically clear, but the method of measurement should be specified because surface plasmon resonance and cell-binding assays can give different values.

Support. Claim 1 covers an unlimited genus of antibodies defined by function. The specification discloses one murine antibody, mAb1, and one xenograft result. There is no common structural feature tying the genus together and no representative number of species. A claim to any antibody meeting two functional limits is not supported by one example.

Enablement. Making antibodies against X may be routine in general, but making antibodies with a sub-nanomolar KD and in vivo efficacy across the genus requires undue experimentation. The statement that humanized variants 'can be generated routinely' is prophetic and does not supply sequences or data. The eight-mouse experiment is small and does not establish breadth.

Industrial applicability is not the problem; the objections are clarity, support and enablement. Claim 1 should be narrowed.

The replacement claims should tie function to the disclosed structure and assay. A workable set is:

1. An isolated antibody comprising the heavy chain variable region CDRs and light chain variable region CDRs of mAb1, as set out in the disclosed sequences, and binding X with a KD of 1 nM or less as measured by surface plasmon resonance.
2. The antibody of claim 1, which reduces tumor volume by at least 40% in the disclosed xenograft assay.
3. A humanized antibody comprising the CDRs of claim 1 and human framework regions.
4. A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
5. The antibody of claim 1 conjugated to a detectable label or cytotoxic agent.
6. A nucleic acid encoding the antibody of claim 1, and a host cell comprising it.

The reasoning is that the CDRs are disclosed, the 40% figure comes from the specification, and the assay is identified. The claim no longer covers any antibody that happens to bind X. The humanized claim is limited to CDR-grafted molecules, which the specification supports as a class even without humanized sequences. If the specification does not literally disclose a 40% threshold, use the exact observed value or a phrasing tied to the experiment. Do not introduce new numerical limits not found in the application.

The PCT must be filed within 12 months of the priority application. The key question is whether the amended claims are supported by the priority document.

• If the amendment only narrows to mAb1, its disclosed CDRs and the disclosed 40% result, the priority document supports the claims and priority should be preserved.
• If the applicant adds new data, new humanized sequences or a new numerical threshold after the priority date, those additions cannot support the priority claim for claims relying on them. The PCT can contain the new matter, but those claims will have the later PCT filing date.
• The applicant should therefore file the PCT with two layers: claims fully supported by the priority document, and fallback claims that use any new data but accept a later effective date.
• The startup should not publicly disclose the new data before filing. If the earlier poster or article already disclosed the broad concept, the PCT cannot recover it.

The practical advice is to file the PCT before the 12-month deadline with the narrowed claims, keep the priority document clean, and use the national phase to decide whether the later data are worth relying on.